Therefore, supplementation of methionine and inhibition of tumour SLC43A2 can normalise methionine metabolism in effector T cells and restore their function, enhancing anti‐tumour immunity in preclinical models.185. This evidence concerns the gene SLC43A2 and neoplasm.